Early assessment of PSA response in patients with mCRPC treated with enzalutamide and abiraterone
| Autor: | A. Oliver Sartor, Ashwin Vasudevamurthy, Brian E. Lewis, Patrick Cotogno, Emma M. Ernst, Jonathan L. Silberstein, Allison H. Feibus, Jeffrey R. Guccione, Elisa Ledet, Charlotte Manogue |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty Treatment response business.industry Psa response urologic and male genital diseases medicine.disease Surgery 03 medical and health sciences Prostate cancer Abiraterone chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis Internal medicine medicine Clinical endpoint Enzalutamide In patient business Psa nadir 030215 immunology |
| Zdroj: | Journal of Clinical Oncology. 35:e574-e574 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2017.35.6_suppl.e574 |
| Popis: | e574 Background: Abiraterone (Abi) and enzaleutamide (Enza) are first-line agents for the treatment of metastatic castrate-resistant prostate cancer (mCRPC). Primary resistance is well-documented, but little data exists for rapid treatment responders. This study intended to further characterize patients with early prostate-specific antigen (PSA) decline. Methods: A single-institution retrospective review was performed on 123 mCRPC patients treated with Abi and/or Enza. PSA was recorded every 4 weeks for the duration of treatment. The primary endpoint was to describe PSA response, including sensitivities and specificities, as a predictor of later treatment response (defined as ≥50% decrease in PSA from baseline). Additional clinical covariates were also evaluated as treatment-response predictors. Results: A PSA response to Abi was achieved in 52/123 (42%) of patients. Median time to PSA nadir was 37 days. 30/52 (58%) patients responded to the drug within 4 weeks. Median length of time on drug was 110 days. A PSA response to Enza was achieved in 21/123 (17%) of patients. Median time to PSA nadir was 140 days. 18/21 (86%) of patients responded to the drug within 4 weeks. Median length of time on drug was 161 days. Conclusions: Percentage of PSA decline and time to drug response for Enza and Abi are important variables that can serve as reliable way for clinicians to predict long-term PSA response. It is vital to make appropriate treatment modifications for patients that do not display early PSA response. [Table: see text] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|